Follow The Filings

FDMT 4D Molecular Therapeutics In

Health Care, filed as 4D MOLECULAR THERAPEUTICS IN (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.4%
  • $4.4M
  • 1 add

In 2026 Q2 James Silverman added to 4D Molecular Therapeutics In.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 0.40%

Who owns FDMT

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.40%, was 0.13% Add +197.8% 334,437 $4.4M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by FDMT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FDMT insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $5.4M sold by 2 insiders under 10b5-1 plans
  1. Scott Bizily Chief Legal Officer
    Planned sale
    $21K 1,635 shares at $12.84 16% of stake
    Traded Oct 16 Filed Oct 20
    ↗
  2. David Kirn See Remarks
    Planned sale
    $754K 58,333 shares at $12.92 7.6% of stake
    Traded Oct 5 Filed Oct 7
    ↗
  3. Scott Bizily Chief Legal Officer
    Planned sale
    $22K 1,635 shares at $13.65 16% of stake
    Traded Sep 16 Filed Sep 22
    ↗
  4. David Kirn See Remarks
    Planned sale
    $811K 58,333 shares at $13.90 7.1% of stake
    Traded Sep 14 Filed Sep 16
    ↗
  5. Scott Bizily Chief Legal Officer
    Planned sale
    $8,176 584 shares at $14.00 6.3% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  6. David Kirn See Remarks
    Planned sale
    $1.1M 69,076 shares at $15.75 7.7% of stake
    Traded Aug 19 Filed Aug 21
    ↗
  7. Scott Bizily Chief Legal Officer
    Planned sale
    $40K 3,270 shares at $12.10 28% of stake
    Traded Aug 13–17 Filed Aug 17
    ↗
  8. David Kirn See Remarks
    Planned sale
    $275K 26,842 shares at $10.23 3.1% of stake
    Traded Aug 4 Filed Aug 5
    ↗
  9. David Kirn See Remarks
    Planned sale
    $125K 12,415 shares at $10.05 1.4% of stake
    Traded Aug 3 Filed Aug 4
    ↗
  10. David Kirn See Remarks
    Planned sale
    $737K 58,333 shares at $12.64 6.2% of stake
    Traded Jul 9–10 Filed Jul 14
    ↗
  11. Scott Bizily Chief Legal Officer
    Planned sale
    $92K 6,566 shares at $14.00 43% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  12. Scott Bizily Chief Legal Officer
    Planned sale
    $118K 9,810 shares at $12.00 53% of stake
    Traded Jun 23 Filed Jun 25
    ↗
  13. David Kirn See Remarks
    Planned sale
    $1.2M 114,746 shares at $10.47 11% of stake
    Traded Jun 22 Filed Jun 23
    ↗
  14. David Kirn See Remarks
    Planned sale
    $19K 1,922 shares at $10.02 0.2% of stake
    Traded Jun 1 Filed Jun 2
    ↗
  15. Scott Bizily Chief Legal Officer
    Planned sale
    $18K 1,635 shares at $10.90 31% of stake
    Traded Dec 16, 2025 Filed Dec 19, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 17 option exercises and 4 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 2.02 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 1.01,2.03 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $20.72M $0.037M $85.21M
Net income -$100.84M -$160.87M -$140.11M
Net margin * -486.6% -434778.4% -164.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $296.59M $434.93M $413.13M
Total non-current assets * $43.3M $125.45M $153.58M
Total assets $339.89M $560.38M $566.71M
Total current liabilities $18.95M $29.15M $43.98M
Total non-current liabilities * $13.11M $20.63M $17.06M
Total equity $307.83M $510.61M $505.66M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$75.79M -$134.58M -$109.08M
Cash from investing $115.72M -$302.44M -$92.97M
Cash from financing $156.83M $337.25M $112.96M
Net change in cash $196.76M -$99.77M -$89.1M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.